OncoCyte Corp (OCX) Stock Rating Upgraded by Zacks Investment Research
OncoCyte Corp (NYSEMKT:OCX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, Chardan Capital began coverage on shares of OncoCyte Corp in a research report on Thursday, February 23rd. They set a “buy” rating and a $6.50 price objective for the company. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $6.81.
Shares of OncoCyte Corp (NYSEMKT:OCX) opened at 5.80 on Friday. OncoCyte Corp has a 12-month low of $3.10 and a 12-month high of $7.95. The company’s market cap is $170.29 million. The stock has a 50 day moving average of $5.41 and a 200 day moving average of $5.39.
OncoCyte Corp (NYSEMKT:OCX) last released its quarterly earnings data on Monday, February 27th. The company reported ($0.11) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.11). On average, equities analysts expect that OncoCyte Corp will post ($0.49) earnings per share for the current fiscal year.
Your IP Address:
OncoCyte Corp Company Profile
OncoCyte Corporation is a development-stage biotechnology company focused in the field of regenerative medicine. The Company is developing molecular cancer diagnostics utilizing a discovery platform that focuses on identifying genetic markers expressed in various types of cancer. It operates through the research and development of diagnostic tests for the detection of cancer segment.
Receive News & Stock Ratings for OncoCyte Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte Corp and related stocks with our FREE daily email newsletter.